AllianceRx Walgreens Prime and Walgreens Gain Access to More Specialty Drugs

Thursday, April 26, 2018 Drug News
Email Print This Page Comment bookmark
Font : A-A+

Industry-leading limited distribution drug (LDD) access means ability to serve 98 percent of specialty members' needs through both LDD and non-LDD medication

ORLANDO, Fla. and DEERFIELD, Ill., April 26, 2018 /PRNewswire/ -- AllianceRx Walgreens

Prime, the combined central specialty and home delivery pharmacy formed by Walgreens and pharmacy benefit manager Prime Therapeutics LLC (Prime), and Walgreens, announce the availability of several new limited distribution drugs for its specialty patients.

The new drugs treat rare conditions such as Huntington's disease, severe asthma and cystic fibrosis (CF), or offer improved treatment protocols for hemophilia in adults and children.

The four drugs now available for AllianceRx Walgreens Prime and Walgreens patients include Austedo® (deutetrabenazine), Fasenra™ (benralizumab), Hemlibra® (emicizumab-kxwh) and Symdeko™ (tezacaftor/ivacaftor and ivacaftor).

  • Austedo is used to treat involuntary body movements associated with Huntington's disease, an incurable, hereditary brain disorder. Distributed by Teva Pharmaceuticals USA, Inc., Austedo is also now available at select Walgreens community-based specialty pharmacies.
  • Fasenra is an add-on maintenance treatment of patients with severe asthma aged 12 years and older. Fasenra is the only respiratory biologic that provides direct, rapid and near-complete depletion of eosinophils (a type of disease-fighting white blood cell) within 24 hours.
  • Hemlibra prevents or substantially reduces bleeds in adults and children with hemophilia A (congenital factor VIII deficiency). Manufactured by Genentech, Hemlibra is the only medicine that can be self-administered once weekly by injection.
  • Symdeko, manufactured by Vertex Pharmaceuticals, treats CF in people 12 years old and older who have two copies of the F508del mutation or one mutation that is responsive to Symdeko. This drug is also now available at select Walgreens community-based specialty pharmacies.

"Continually expanding on our industry-leading limited distribution drug list demonstrates our passion and commitment to making sure patients have access to the medications they need, including those that may be hard to find," says Joel Wright, chief executive officer for AllianceRx Walgreens Prime. "We are pleased to offer these medications as additional options to help treat patients who have been diagnosed with these serious conditions, and continue to work with Walgreens at the community-based specialty pharmacies as well."

About AllianceRx Walgreens PrimeAllianceRx Walgreens Prime (alliancerxwp.com) is a specialty and home delivery pharmacy that strives to provide exceptional care throughout a patient's treatment journey with the medications they need every day. Formed in 2017 through a collaboration between Walgreens, one of the nation's largest chain drug stores, and Prime Therapeutics, a leading pharmacy benefit manager, the company offers tools and resources for patients, providers and health plans to deliver the optimal health outcomes. The company is headquartered in Orlando, Fla. and its pharmacies are accredited by several national pharmacy accreditation services.

About WalgreensWalgreens (walgreens.com), a provider of trusted care in communities since 1901, is included in the Retail Pharmacy USA Division of Walgreens Boots Alliance, Inc. (NASDAQ: WBA), the first global pharmacy-led, health and wellbeing enterprise. Approximately 8 million customers interact with Walgreens in stores and online each day, using the most convenient, multichannel access to consumer goods and services and trusted, cost-effective pharmacy, health and wellness services and advice. Walgreens operates 8,100 drugstores with a presence in all 50 states, the District of Columbia, Puerto Rico and the U.S. Virgin Islands, along with its omnichannel business, Walgreens.com. Approximately 400 Walgreens stores offer Healthcare Clinic or other provider retail clinic services.

Media ContactsAdrienne Foley | adrienne.foley@primetherapeutics.com | 612.777.6259Scott Goldberg | scott.goldberg@walgreens.com | 847.315.7649

 

Cision View original content:http://www.prnewswire.com/news-releases/alliancerx-walgreens-prime-and-walgreens-gain-access-to-more-specialty-drugs-300637480.html

SOURCE AllianceRx Walgreens Prime



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store